CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - OCULAR THERAPEUTIX INC

Explicit Guidance:

• NDA Submission Timing: Targeting submission of the New Drug Application (NDA) for X-Paxly in Q4 (current year), based on a single adequate and well-controlled trial plus confirmatory evidence under the 505(b)(2) pathway.
• Cash Runway: Cash position of nearly $600 million at June 30 is expected to sustain operations into 2028.
• Commercialization Capital: No explicit dollar amount or timing guidance provided for U.S. launch capital requirements; management states guidance "explicitly excludes" the full cost of commercialization and will consider "flexible ways" to secure capital (equity, debt, royalty, or ex-US partners) only if/when necessary closer to launch.

Business-Segment Outlook:

• Product Launch (X-Paxly): Positioning as a maintenance drug (tunable hydrogel) for wet AMD, distinct from bolus injections.
• Market Positioning: Expecting to be the sole competitor in the maintenance drug category for wet AMD following iPoint's failure to meet non-inferiority endpoints; management views Kodiak's Tarkosamab as a bolus competitor competing with standard of care (Lucentis, Avastin, Eylea), not directly with X-Paxly.
• Clinical Pipeline (SOL-R): Confident in the success of the SOL-R trial due to bespoke patient selection (treatment-naive patients only) and robust trial design, despite earlier delays in top-line data expectations moving from Q1 2027 to Q1 2028 (post-amendment).
• Regulatory Strategy: Operating on an accelerated 505(b)(2) pathway to minimize time to approval; management believes no Advisory Committee meeting will be required due to the established VEGF suppression mechanism.

Market and Competitive Outlook:

• Competitive Landscape (iPoint): Following iPoint's dual Phase 3 failure on non-inferiority endpoints, management anticipates a clear path forward for X-Paxly with no competition in the maintenance space.
• Competitive Landscape (Kodiak): Dismisses Kodiak's Tarkosamab (non-inferior to aflibercept with 54% 6-month dosing) as a direct threat, categorizing it as a "bolus" agent rather than a "maintenance" agent.
• Disease Understanding: Identifies a structural market inefficiency where the retina community is ~75 years behind oncology in disease stratification and lacks biomarkers/genetic markers, necessitating highly specific clinical trial designs.

Macro / Industry Outlook:

• Clinical Trial Dynamics: Notes a structural shift away from large 2,000–3,000 patient studies (typical of Genentech/Roche) toward smaller, bespoke studies requiring rigorous patient selection to mitigate variability in wet AMD, DME, and RVO.
• Adverse Event Visibility: Anticipates that full adverse event (AE) profiles for competitors like Kodiak may not be fully visible yet, suggesting only ~25% of AEs have been seen so far in recent data releases.

Strategic Initiatives:

• Trial Amendment (SOLAR): Executed a strategic amendment to SOLAR to add a key secondary endpoint of superiority versus aflibercept 8mg at Week 96 and extended masking. This decision was made to avoid "major amendments" mid-review that would delay the accelerated approval timeline.
• Team Scaling: Has scaled the internal team specifically for a "retina for retina" U.S. commercial launch of X-Paxly.
• Pathway Formalization: Successfully formalized a single trial approval pathway with the FDA.

Risks and Headwinds to Outlook:

• Trial Design Sensitivity: Success is contingent on proper patient selection (treatment-naive vs. previously treated); mixing populations could lead to failure as seen with competitors.
• Data Maturity: Full AE data for alternative bolus injections (like Kodiak) remains incomplete, potentially obscuring long-term safety signals.
• Capital Uncertainty: While currently well-capitalized, the specific funding mix (equity/debt/partnership) required for the commercial launch remains undetermined and is a potential future risk.
• Regulatory Timelines: Any "major amendment" during the FDA review process (which the company avoided via the SOLAR amendment) could reset the clock and delay approval.

Management Tone on the Future:

• Confidence Level: High confidence in the SOL-R success and NDA approval; describes FDA interactions as "collaborative," "supportive," and "absolutely in lockstep."
• Comparative Optimism: Expresses relief and strategic clarity following iPoint's failure, viewing the competitive landscape as "clear path forward... without any kind of competition whatsoever" in the maintenance category.
• Hedges/Context: Acknowledges the broader industry failure rate (9 out of 10 drugs fail) and the tragic nature of patient dropout rates (40% in year one), framing X-Paxly as a necessary solution to "intolerable" real-world outcomes.

Miscellaneous:

• Mechanism of Action: X-Paxly utilizes a tunable hydrogel with a TKI (tyrosine kinase inhibitor), distinct from anti-VEGF biologics, though it achieves VEGF suppression.
• Trial Metrics: SOL1 achieved a p-value of <0.0006 against the FDA's threshold for robustness (<0.001), hitting a superiority endpoint for the first time in the history of the treatment class.